FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition
Published on November 9, 2026
Today, the U.S. Food and Drug Administration (FDA) announced that patients and healthcare providers should be aware of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rare condition that can result in acute, painless, decreased vision in one […]
The post FDA Requires Safety Labeling Changes for GLP-1 RAs Due to Potential Increased Risk of Rare But Serious Eye Condition appeared first on Endocrine News.